EA002167B1 - Вакцинная композиция против малярии - Google Patents

Вакцинная композиция против малярии Download PDF

Info

Publication number
EA002167B1
EA002167B1 EA199900069A EA199900069A EA002167B1 EA 002167 B1 EA002167 B1 EA 002167B1 EA 199900069 A EA199900069 A EA 199900069A EA 199900069 A EA199900069 A EA 199900069A EA 002167 B1 EA002167 B1 EA 002167B1
Authority
EA
Eurasian Patent Office
Prior art keywords
protein
vaccine composition
composition according
malaria
adjuvant
Prior art date
Application number
EA199900069A
Other languages
English (en)
Russian (ru)
Other versions
EA199900069A1 (ru
Inventor
Джозеф Коэн
Original Assignee
Смитклайн Бичем Байолоджикалз С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Смитклайн Бичем Байолоджикалз С.А. filed Critical Смитклайн Бичем Байолоджикалз С.А.
Publication of EA199900069A1 publication Critical patent/EA199900069A1/ru
Publication of EA002167B1 publication Critical patent/EA002167B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EA199900069A 1996-08-02 1997-07-31 Вакцинная композиция против малярии EA002167B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9616351.4A GB9616351D0 (en) 1996-08-02 1996-08-02 Vaccine composition
PCT/EP1997/004326 WO1998005355A1 (en) 1996-08-02 1997-07-31 Vaccine composition against malaria

Publications (2)

Publication Number Publication Date
EA199900069A1 EA199900069A1 (ru) 1999-10-28
EA002167B1 true EA002167B1 (ru) 2002-02-28

Family

ID=10797980

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199900069A EA002167B1 (ru) 1996-08-02 1997-07-31 Вакцинная композиция против малярии

Country Status (32)

Country Link
US (2) US20020172692A1 (https=)
EP (2) EP0957933B1 (https=)
JP (1) JP2000517295A (https=)
KR (1) KR20000029747A (https=)
CN (1) CN1241639C (https=)
AP (1) AP1166A (https=)
AR (1) AR008799A1 (https=)
AT (1) ATE394119T1 (https=)
AU (1) AU706303B2 (https=)
BG (1) BG63290B1 (https=)
BR (1) BR9710913A (https=)
CA (1) CA2262402A1 (https=)
CO (1) CO4650186A1 (https=)
CZ (1) CZ290826B6 (https=)
DE (1) DE69738672D1 (https=)
DZ (1) DZ2283A1 (https=)
EA (1) EA002167B1 (https=)
GB (1) GB9616351D0 (https=)
ID (1) ID17860A (https=)
IL (1) IL128318A (https=)
MA (1) MA24291A1 (https=)
MY (1) MY116128A (https=)
NO (1) NO319844B1 (https=)
OA (1) OA10969A (https=)
PE (1) PE97298A1 (https=)
PL (1) PL188741B1 (https=)
SK (1) SK282438B6 (https=)
TR (1) TR199900195T2 (https=)
UA (1) UA68336C2 (https=)
UY (1) UY24654A1 (https=)
WO (1) WO1998005355A1 (https=)
ZA (1) ZA976815B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9915204D0 (en) * 1999-06-29 1999-09-01 Smithkline Beecham Biolog Vaccine
AU2003285932A1 (en) 2002-10-23 2004-05-13 Glaxosmithkline Biologicals S.A. Methods for vaccinating against malaria
NZ548166A (en) * 2003-12-01 2010-06-25 Meiji Dairies Corp Peptide inhibiting angiontensin converting enzyme
GB0513421D0 (en) * 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
DK1909830T3 (da) * 2005-08-02 2011-12-19 Novartis Vaccines & Diagnostic Formindskelse af interferens mellem olieholdige adjuvanser og antigener indeholdende overfladeaktivt middel
GB0614254D0 (en) * 2006-07-18 2006-08-30 Smithkline Beecham Biolog Vaccine
US9364525B2 (en) * 2006-07-18 2016-06-14 Glaxosmithkline Biologicals Sa Vaccines for malaria
JP5814507B2 (ja) 2006-09-07 2015-11-17 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
KR20100068390A (ko) 2007-08-13 2010-06-23 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
AU2008339980A1 (en) * 2007-12-21 2009-07-02 Glaxosmithkline Biologicals S.A. Vaccines for malaria
WO2009080803A1 (en) 2007-12-24 2009-07-02 Glaxosmithkline Biologicals S.A. Vaccines for malaria
US20120015000A1 (en) * 2008-06-30 2012-01-19 David Lanar Malaria vaccine of self-assembling polypeptide nanoparticles
CA3002946C (en) * 2009-11-05 2021-11-02 The United States Of America As Represented By The Secretary Of The Navy Plasmodium falciparum sporozoite and liver stage antigens
BR112013004582A2 (pt) 2010-09-27 2016-09-06 Crucell Holland Bv método para induzir uma resposta imune em um sujeito contra um antígeno de um parasita que causa a malária
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
US20130122038A1 (en) 2011-11-14 2013-05-16 The United States Of America As Represented By The Secretary Of The Department Heterologous prime-boost immunization using measles virus-based vaccines
US9169304B2 (en) 2012-05-01 2015-10-27 Pfenex Inc. Process for purifying recombinant Plasmodium falciparum circumsporozoite protein
CN104338129B (zh) * 2013-07-26 2017-05-24 中国科学院上海巴斯德研究所 雷帕霉素作为疫苗佐剂的用途及制备方法
US10695424B2 (en) 2016-12-07 2020-06-30 Glaxosmithkline Biologicals S.A. Method of making a liposome composition
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
GB2600653B (en) 2017-05-30 2022-11-02 Glaxosmithkline Biologicals Sa Novel methods
BR112020010790A2 (pt) 2017-12-01 2020-11-10 Glaxosmithkline Biologicals S.A. purificação da saponina
WO2020245207A1 (en) 2019-06-05 2020-12-10 Glaxosmithkline Biologicals Sa Saponin purification

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3280028D1 (en) * 1981-05-21 1989-12-28 Wellcome Found Protozoal antigen
ES8800273A1 (es) * 1985-03-28 1987-11-01 Univ New York Perfeccionamientos en la fabricacion de conjugados de proteinas portadores de antigenos inmunogenicos para vacunas contra la malaria
GB8819209D0 (en) * 1988-08-12 1988-09-14 Research Corp Ltd Polypeptide & dna encoding same
GB9012580D0 (en) * 1990-06-06 1990-07-25 Univ Nijmegen Novel protein
FR2679776A1 (fr) * 1991-07-31 1993-02-05 Pasteur Institut Melange de constituants peptidiques ayant des proprietes vaccinantes contre le paludisme, notamment du a plasmodium falciparum.
AU2927892A (en) * 1991-11-16 1993-06-15 Smithkline Beecham Biologicals (Sa) Hybrid protein between cs from plasmodium and hbsag
US6169171B1 (en) * 1992-02-27 2001-01-02 Smithkline Beecham Biologicals (S.A.) Hybrid protein between CS from plasmodium and HBSAG
CA2138997C (en) * 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
AUPM368994A0 (en) * 1994-02-04 1994-02-24 Saramane Pty Ltd Malaria merozoite antigen subunit vaccine
FR2744724B1 (fr) * 1996-02-14 2002-08-02 Pasteur Institut Proteine recombinante contenant un fragment c-terminal de la proteine msp-1 d'un plasmodium infectieux pour l'homme pour la production de vaccins anti-paludiques
FR2744723A1 (fr) * 1996-02-14 1997-08-14 Pasteur Institut Proteine recombinante contenant un fragment c-terminal d'une proteine msp-1 d'un plasmodium infectieux pour l'homme pour la production de vaccins anti-paludiques

Also Published As

Publication number Publication date
AP9901448A0 (en) 1999-03-31
CZ290826B6 (cs) 2002-10-16
MA24291A1 (fr) 1998-04-01
AP1166A (en) 2003-06-30
AU4204097A (en) 1998-02-25
EP0957933A1 (en) 1999-11-24
EP1623720A2 (en) 2006-02-08
TR199900195T2 (xx) 1999-04-21
CZ29299A3 (cs) 1999-06-16
OA10969A (en) 2003-03-04
DZ2283A1 (fr) 2002-12-25
WO1998005355A1 (en) 1998-02-12
IL128318A0 (en) 2000-01-31
UA68336C2 (en) 2004-08-16
EP1623720A3 (en) 2006-02-22
MY116128A (en) 2003-11-28
IL128318A (en) 2002-04-21
PL188741B1 (pl) 2005-04-29
CN1241639C (zh) 2006-02-15
CN1231613A (zh) 1999-10-13
AR008799A1 (es) 2000-02-23
EP0957933B1 (en) 2008-05-07
DE69738672D1 (de) 2008-06-19
GB9616351D0 (en) 1996-09-11
AU706303B2 (en) 1999-06-10
CA2262402A1 (en) 1998-02-12
KR20000029747A (ko) 2000-05-25
UY24654A1 (es) 2001-08-27
US20060292170A1 (en) 2006-12-28
EA199900069A1 (ru) 1999-10-28
PE97298A1 (es) 1999-02-14
BR9710913A (pt) 1999-08-17
BG103141A (en) 1999-08-31
ZA976815B (en) 1998-05-11
NO990464L (no) 1999-02-01
PL331424A1 (en) 1999-07-19
US20020172692A1 (en) 2002-11-21
NO990464D0 (no) 1999-02-01
JP2000517295A (ja) 2000-12-26
ATE394119T1 (de) 2008-05-15
CO4650186A1 (es) 1998-09-03
ID17860A (id) 1998-01-29
SK11599A3 (en) 2000-03-13
SK282438B6 (sk) 2002-02-05
NO319844B1 (no) 2005-09-19
BG63290B1 (bg) 2001-09-28

Similar Documents

Publication Publication Date Title
EA002167B1 (ru) Вакцинная композиция против малярии
Danforth et al. Genetically engineered antigen confers partial protection against avian coccidial parasites
EA003832B1 (ru) Ген-доставочный комплекс для чрескожной доставки чужеродного генетического материала в антиген-презентирующие клетки и способы его использования
Kongkasuriyachai et al. Potent immunogenicity of DNA vaccines encoding Plasmodium vivax transmission-blocking vaccine candidates Pvs25 and Pvs28—evaluation of homologous and heterologous antigen-delivery prime-boost strategy
Alves et al. Plasmodium falciparum merozoite surface protein 3 as a vaccine candidate: A brief review
US20030161838A1 (en) Isolation and purification of P. falciparum merozoite protein-142 vaccine
AU762945B2 (en) Recombinant multivalent malarial vaccine against plasmodium falciparum
ES2248816T3 (es) Moleculas polipeptidicas de fase preeritrocitica del paludismo.
DE602004006493T2 (de) Zusammensetzungen und Verfahren zur Erzeugung einer schützenden Immunantwort gegen Malaria
US20040067236A1 (en) Immunogenic compositions comprising liver stage malarial antigens
BG65569B1 (bg) Химерен ген кодиращ антигенни детерминанти на четири протеина на l. infantum
US20030133944A1 (en) Vaccine composition against malaria
EP0241725B1 (en) Improvements in and relating to vaccines
EP0254862A1 (en) Vaccines against protozoan parasites
US6458359B1 (en) Chimeric gene formed by the dna sequences that encode the antigenic determinants of four proteins of l. infantum and protein encoded by said gene, and pharmacuetical composition useful for preventing and/or treating leishmaniosis in animals or humans
US20110262469A1 (en) Malaria vaccine based on fragments and combination of fragments of the cs protein of plasmodium vivax
Chedid Use of Muramyl Peptides in Synthetic and Semisynthetic Vaccines
Chai The humoral response to a chemically defined synthetic vaccine comprised of epitopes derived from the circumsporozoite protein of Plasmodium berghei
JP2002533474A (ja) エル．インファンタム（Ｌ．ｉｎｆａｎｔｕｍ）の４つのタンパク質の抗原決定基をコードするキメラ遺伝子

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU